Epigenetic factors have been implicated in the regulation of CD4 + T cell differentiation. Jmjd3 plays a role in many biological processes, but its in vivo function in T cell differentiation remains unknown. Here, we report that Jmjd3 ablation promotes CD4 + T cell differentiation into Th2 and Th17 cells in the small intestine and colon, and inhibits T cell differentiation into Th1 cells under different cytokine-polarizing conditions and in a Th1-dependent colitis model. Jmjd3 deficiency also restrains the plasticity of the conversion of Th2, Th17 or Treg cells to Th1 cells. The skewing of T cell differentiation is concomitant with changes in the expression of key transcription factors and cytokines. H3K27me3 and H3K4me3 levels in Jmjd3-deficient cells are correlated with altered gene expression through interactions with specific transcription factors. Our results identify Jmjd3 as an epigenetic factor in T cell differentiation via changes in histone methylation and target gene expression.
Introduction
CD4 + T cells consist of several subsets, including Th1, Th2, Th17, and regulatory T (Treg) cells. Th1 cells secrete interleukin (IL)-2 and interferon (IFN)-γ and express T-bet transcriptional factor, whereas Th2 cells secrete IL-4, IL-5, and IL-13, express GATA-3, and activate B cells to become antibody-secreting plasma cells 1, 2 . Th17 cells are a distinct CD4 + Th cell lineage, secreting a unique set of cytokines including IL-17, IL-21, and IL-22 3, 4 . Th17 cell development and differentiation require the key transcriptional factors, retinoic acid-related orphan receptor (ROR)γt and RORα 5, 6 . Treg cells, which express the master transcriptional regulator Foxp3, suppress host immune responses and induce selftolerance 7, 8 .
A growing body of evidence suggests that CD4 + Th cells play a central role in initiating and maintaining immune responses against cancer and infectious and autoimmune diseases [8] [9] [10] [11] . Dysregulation of CD4 + T cell differentiation is associated with various autoimmune and inflammatory diseases, including myelodysplastic syndromes and systemic lupus erythematosus [12] [13] [14] . Regulation of CD4 + T cell differentiation is essential to maintaining the appropriate balance among CD4 + T cell subsets to support immune homeostasis and prevent autoimmunity. Therefore, understanding the mechanisms regulating and controlling CD4 + T cell differentiation into various subsets is of critical importance to develop innovative treatments. CD4 + T subset differentiation is tightly regulated by many signaling molecules, including signal transducer and activator of transcription (STAT) proteins, interferon regulatory factor 4 (IRF4), and runt-related transcription factor 1 (RUNX1) 2, 15 . In addition to transcription factors, recent studies have shown that epigenetic factors control the specificity and plasticity of T cell subsets [16] [17] [18] [19] . These transcriptional factors and epigenetic regulators bind to both shared and cell-specific regulatory regions (promoters and enhancers) among various T cell lineages and thereby, positively or negatively regulate gene expression depending upon the cofactors present 20 .
It is well-known that gene expression is epigenetically regulated through DNA methylation and covalent chromatin modifications, such as histone acetylation, phosphorylation, ubiquitination, sumoylation, and methylation. Histone methylation state is dynamically regulated by histone methyltransferases and demethylases [21] [22] [23] [24] [25] . Trimethylation of histone 3 at lysine 4 (H3K4) is usually associated with gene activation, whereas trimethylation of histone 3 at lysine 27 (H3K27) is associated with gene repression [21] [22] [23] [24] [25] . Polycomb repressive complex 2, containing the H3K27 methyltransferase, Ezh2, dimethylates and trimethylates H3K27 (H3K27me2/3) 24, 26 . Recently, the H3K27 demethylase Jmjd3 (also known as KDM6B) was found to catalyze the demethylation of H3K27me2/3 in vitro [27] [28] [29] [30] [31] [32] . Jmjd3 is induced by vitamin D and proinflammatory stimuli in macrophages and is required for Ink4a-Arf, Nodal, and Irf4 expression in fibroblasts, mouse embryonic stem cells, and macrophages, respectively [33] [34] [35] [36] [37] . In addition, Jmjd3 regulates macrophage differentiation, in particular, type 2 macrophages 37, 38 . Although Jmjd3 has been shown to interact with the Th1 master regulator, T-bet 39, 40 , the in vivo function of Jmjd3 in T cell differentiation remains unknown.
In this study, we generated T cell-specific Jmjd3-deficient mice and found that Jmjd3 deletion promotes Th2 and Th17 differentiation and inhibits Th1 and Treg cell differentiation. Our findings indicate that Jmjd3 regulates CD4 + T cell differentiation by mediating the methylation status of H3K27 and/or H3K4 in target genes and regulating target gene expression. These loci-specific effects of Jmjd3 on target gene expression are mediated through interactions with specific transcription and epigenetic factors.
Results

Generation of mice with T cell-specific deletion of Jmjd3
To determine the physiological role of Jmjd3 in T cells, we generated T cell-specific Jmjd3-deficient (Jmjd3 cKO) mice. We generated Jmjd3 flox/flox (Jmjd3 f/f ) mice by targeting exons 15-21 (encoding the JmjC-catalytic domain) using a Cre-LoxP system 41 . Jmjd3 f/f mice were crossed with CD4-Cre mice to generateJmjd3 cKO mice ( Supplementary Fig. 1a ). Jmjd3 cKO mice were genotyped by PCR analysis (Supplementary Fig. 1b ). Reverse transcription (RT)-PCR and western blot analyses confirmed the loss of Jmjd3 mRNA and protein in Jmjd3-deficient T cells, but not in B cells ( Supplementary Fig. 1c, d ). Jmjd3 cKO mice survived and grew normally.
Jmjd3 skews T cell differentiation in vivo
Recent studies have shown that Jmjd3 interacts with T-bet, a master transcription factor in Th1 cell differentiation, in a histone demethylase activity-independent manner 39, 40 . However, the in vivo function of Jmjd3 in T cell differentiation remains unknown. To address this, we used fluorescence-activated cell sorting (FACS) analysis to determine the percentages of CD4 + T cell subsets in lymphocytes isolated from small intestine, spleen, lymph node (LN), and colon of wild-type (WT) and Jmjd3 cKO mice. Compared with WT mice, IFN-γ-producing Th1 cells were slightly increased in the LN and colon in Jmjd3 cKO mice, but decreased in the small intestine and spleen. IL-4-producing Th2 cells were increased in the small intestine and colon, but not significantly changed in spleen or LN (Fig. 1a-d) . The percentage of IL-17-producing Th17 cells was substantially higher in the small intestines of Jmjd3 cKO mice compared with WT mice (14.8% vs. 3.8%) and in the colons (17.5% vs. 5.2%) of Jmjd3 cKO mice compared with WT mice (Fig. 1a,d ). We did not observe any appreciable changes in lymphatic Th17 cells between WT and Jmjd3 cKO mice (Fig. 1c) . Foxp3-expressing Treg cells were slightly higher in the small intestine, spleen, and LN (Fig. 1a-c) , but not in the colon of Jmjd3 cKO mice compared with WT mice. To determine the effects of Jmjd3 on thymic and splenic natural Treg (nTreg) cell populations, WT and Jmjd3 cKO Foxp3-GFP reporter mice were generated. FACS analysis revealed that the percentage of thymic GFP + nTreg cells was approximately 50% lower in Jmjd3 cKO mice than in WT mice. In contrast, the splenic nTreg cell population percentage was similar between WT and Jmjd3 cKO mice (9.7% vs. 11.3%) (Fig. 1e) . These results suggest that Jmjd3 ablation markedly promotes Th17 and Th2 cell differentiation in the small intestine and colon and decreases Th1 cell differentiation in the small intestine and spleen. However, its effects on lymphatic Th1, Th2, Th17, and Treg cells are relatively small.
Jmjd3 alters T cell differentiation and cytokine expression
To determine whether Jmjd3 ablation affects CD4 + T cell differentiation under different cytokine-polarizing conditions, the percentage of IFN-γ-, IL-4-, and IL-17-producing T cells and Foxp3-expressing T cells was analyzed in WT and Jmjd3 cKO purified naïve CD4 + T cells cultured under ThN (non-skewing cytokines), Th1 (in the presence of IL-12), Th2 (in the presence of IL-4), Th17 (in the presence of transforming growth factor [TGF-β] and IL-6), and Treg cell (in the presence of TGF-β and IL-2) conditions for 4 days. Jmjd3 ablation reduced the percentage of IFN-γ-producing Th1 cells from 50.1% to 6.2% and increased IL-4-producing Th2 cells from 3.2% to 48.6% under ThN conditions (Fig. 2a) . Under Th1 conditions, Jmjd3 ablation also reduced the percentage of IFN-γ-producing Th1 cells. The percentage of T cells producing both IFN-γ and IL-4 was slightly higher in Jmjd3-deficient T cells compared with WT T cells (10.3% vs. 6.2%) under ThN conditions and significantly higher under Th1-stimulating cell culture conditions (11.3% vs. 2.2%) (Fig.  2a) , suggesting that Jmjd3-deficient T cells are readily differentiated into Th2 cells. Under Th2 conditions, Jmjd3-deficient T cells slightly increased in their differentiation into IL-4 producing Th2 cells and slightly decreased into IFN-γ-producing Th1 cells or into IFN-γ-and IL-4-producing cells. However, these changes were not statistically significant, suggesting that exogenous cytokines under Th2 conditions may mask the intrinsic difference between WT and Jmjd3-deficient T cells. Th17 cell differentiation was increased in Jmjd3-deficient T cells under Th17-stimulating conditions (Fig. 2b) . In contrast, the inducible Treg cell population was markedly reduced under Treg cell conditions in Jmjd3-deficient T cells compared with WT T cells (34.3% vs. 63.1%) (Fig. 2b) . Jmjd3 ablation affects cytokine production of freshly isolated naïve CD4 + T cells stimulated with anti-CD3 and anti-CD28. IFN-γ production was significantly reduced in Jmjd3-deficient CD4 + T cells at 12, 24, and 48 h (p < 0.01), whereas IL-4 production was markedly increased at 24 and 48 h (p < 0.05 and p < 0.01, respectively) (Fig. 2c) . To determine whether the increased IL-4 production was due to the early decreased IFN-γ production, we treated cultured T cells with exogenous IFN-γ and measured IL-4 production. Exogenous IFN-γ reduced IL-4 production in both WT and Jmjd3-deficient T cells; however, the Jmjd3-deficient T cells still produced higher amounts of IL-4 compared with WT T cells (Fig. 2d) , suggesting that Jmjd3-deficient T cells preferentially polarize to Th2. Similarly, exogenous IFN-γ suppressed IL-4 producing Th2 cells in both WT and Jmjd3-deficient T cells. However, exogenous IFN-γ suppressed IL-4 producing Th2 cells to a greater extent in WT compared with Jmjd3-deficient T cells (Fig. 2e) . Taken together, these data indicate that Jmjd3 deficiency results in a Th1 to Th2 shift in the CD4 + T cell population.
Jmjd3 ablation affects master regulators of T cell fate
We hypothesized that Jmjd3 deletion may alter the expression of key T cell lineage-specific transcription factors, including T-bet (Th1; encoded by Tbx21), Gata3 (Th2), RORγt (Th17; encoded by Rorc), and Foxp3 (Treg), as well as epigenetic factors and potential target genes. Real-time PCR analysis of T cell differentiation-related genes was performed on RNA isolated from WT and Jmjd3-deficient CD4 + T cells cultured under various cytokinepolarizing conditions for 2 days. Tbx21, Foxo1, Cd44, and Cxcr3 expression levels were markedly lower under ThN and Th1 cell culture conditions in Jmjd3-deficient T cells than in WT T cells (Fig. 2f) . In contrast, Gata3 expression was increased under ThN and Th2 conditions in Jmjd3-deficient T cells compared with WT T cells (Fig. 2f) (Fig. 2f) . In contrast to Tbx21, Gata3, Foxp3, Rorc, and Irf4, little or no difference was observed in Maf and Kdm6A (also known as UTX) expression. Consistent with Tbx21 and Gata3 expression based on real-time PCR results, intracellular staining analysis of T-bet and Gata3 expression also showed a lower level of T-bet and a higher level of Gata3 protein in Jmjd3-deficient T cells than in WT T cells under ThN culture conditions (Fig. 2g) . To determine whether chemokines or chemokine receptors, which might affect tissue migration, are changed between WT and Jmjd3-deficient T cells, CD4 + T cells were isolated from Jmjd3 cKO mice and showed decreased expression of several chemokine receptors, including Ccr2, Ccr4, Ccr8 and Cxcr3, whereas Ccr9 expression was increased in these cells. However, expression of CD103 and other chemokine receptors was unchanged ( Supplementary Fig. 2 ). Taken together, these results suggest that Jmjd3 ablation inhibits Th1 and Treg differentiation and promotes Th2 and Th17 differentiation by regulating the expression of key transcription factors. Altered expression of chemokine receptors, such as Ccr2, Ccr4, Ccr8, Cxcr3, and Ccr9 might be responsible for the migration of differentiated T cells to specific sites such as small intestines and colons.
Jmjd3-deficient T cells limit colitis
Having established that Jmjd3 ablation alters CD4 + T cell differentiation in vitro, we next sought to validate these findings in vivo using a Th1-dependent colitis model. Intraperitoneal (i.p.) adoptive transfer of freshly isolated and purified naïve WT CD4 + T cells into lymphopenic Rag2 −/− γc −/− mice caused spontaneous T cell activation and inflammatory colitis, leading to body weight loss (Fig. 3a) . In contrast, Rag2 −/− γc −/− mice receiving naïve CD4 + T cells from Jmjd3 cKO mice developed a milder colitis, with a body weight loss less than that of mice receiving WT T cells ( (Fig. 4c) . We also examined the plasticity of Treg cells differentiated from WT and Jmjd3-deficient mice. Naïve CD4 + T cells isolated from WT and Jmjd3 cKO mice were differentiated under Treg conditions for 4 days, and then exposed to Th1, Th2 or Th17-inducing conditions for 2 days. Treg cell conversion into IFN-γ-producing cells and IFN-γ/Foxp3-producing Th1 cells decreased from 12.4% to 3.2% and 10.8% to 2.4%, respectively, in Jmjd3 cKO T cells compared with WT T cells. Treg cell conversion into IL-17-producing cells and IL-17/ Foxp3-producing cells increased from 2.6% to 10.4% and 0.5% to 2.4%, respectively, in Jmjd3 cKO T cells compared with WT T cells. (Fig. 4d) . A slightly lower percentage of WT Treg cells, compared with Jmjd3 cKO cells, were converted to Th2 cells (Fig. 4d) . Furthermore, using an anti-CD3 antibody-induced mouse model of tolerance 42 , we showed a dramatic increase in intestinal Th17 cells in Jmjd3 cKO T cells at day 8 after in vivo Th17 differentiation compared with WT T cells (Fig. 4e) . Taken together, our results suggest that Jmjd3 is required for Th1 differentiation, and its ablation reduces the plasticity of Th2, Th17, and Treg cell conversion into Th1 cells.
Decreased T-bet, CD44, and CXCR3 in Jmjd3-cKO T cells
Since T-bet is a critical transcription factor for Th1 cell differentiation 43 , we next investigated Jmjd3 regulation of T-bet and its target genes. CD44 is expressed at an early stage in T cell development in the thymus, and is regulated by Jmjd3 42 . Indeed, we found that CD44 expression was significantly decreased in Jmjd3-deficient ThN and Th1 cells, single-positive (SP) CD4 + thymocytes and splenocytes (Fig.2f, Supplementary Fig. 2 ). We further analyzed CD44 low (CD44 − ) and CD44 high (CD44 + ) CD4 + SP thymic T cell populations and determined T-bet expression by FACS analysis. T-bet protein was reduced in the Jmjd3-deficient CD44 high T cell population compared with the WT CD44 high T cell population, whereas little or no T-bet was detected in the WT or Jmjd3-deficient CD44 low T cell population (Fig. 5a) . Furthermore, we found downregulated CD44 and CXCR3 (T-bet target genes) expression, or fewer numbers of cells expressing CD44, in Jmjd3-deficient T cells compared with WT T cells (Fig. 5b, 5c ). To validate our findings in vivo, CXCR3 and CD44 expression were determined in splenocytes isolated from Rag2 −/− γc −/− mice injected with WT or Jmjd3 cKO naïve CD4 + T cells. Percentage of T cells, expressing both CXCR3 and CD44, was downregulated in Jmjd3-deficient T cells compared with WT T cells, (Fig.  5d ). These findings suggest that Jmjd3 deletion reduces the expression of T-bet, CXCR3, and CD44 in CD4 + T cells, or Jmjd3-deficient T cells contain fewer cells expressing T-bet, CXCR3, and CD44.
Jmjd3 alters target gene methylation of H3K27 and H3K4
To determine the mechanisms by which Jmjd3 regulates target gene expression, we tested whether Jmjd3 ablation affects global histone methylation in T cells. H3K27me2 and H3K27me3, but not H3K27me1, levels were increased in Jmjd3-deficient thymic CD4 + SP T cells compared with WT, whereas appreciable changes in H3K4 methylation were not observed (Fig. 6a, Supplementary Fig. 3a , and Supplementary Table 1 ). This suggests that Jmjd3 deletion specifically increases H3K27 dimethylation and trimethylation in CD4 + T cells. ChIP-Seq analysis on WT and Jmjd3-deficient CD4 + T cells revealed that among the 35,000 RefSeq genes, 2754 genes had increased H3K27me3 levels at approximately 2 kilobases around the transcription start site (TSS) in Jmjd3-deficient CD4 + T cells compared with WT controls. H3K27me3 levels were decreased in 811 genes ( Fig. 6b and Supplementary Table 1 ). H3K4me3 levels were increased in 404 genes and decreased in 114 genes in Jmjd3-deficient CD4 + T cells compared with WT ( Fig. 6b and Supplementary Table 1 ). Analysis of average H3K27me3 levels of the differentially methylated genes revealed that total H3K27me3 methylation levels were increased in both promoter regions and gene bodies in Jmjd3-deficient CD4 + T cells compared with WT cells (Fig. 6c) . H3K4me3 is generally correlated with active transcription, whereas H3K27me3 is associated with gene repression. Chromatin regions containing high levels of both H3K4me3 and H3K27me3 are known as 'bivalent domains', which are silenced and postulated to be 'poised' for activation 44, 45 . T cell-related genes were classified into three groups according to H3K27me3 and H3K4me3 status, and significant differences were found between WT and Jmjd3-deficient CD4 + T cells. Group I genes, including Cd44, Ccnd2, Ifng, Irf4, Ccr2, and Fosl2, in Jmjd3-deficient CD4 + T cells, harbored bivalent domains with increased H3K27me3 and decreased H3K4me3 levels ( Fig. 6d and Supplementary Fig. 4a ), which paralleled decreased gene expression. Group II genes, including Foxp3, Stat3, Tgfß1, Cxcr3, Cxcr6, Ccr8, and Ccr4, had decreased H3K4me3 and unchanged H3K27me3 levels in Jmjd3-deficient CD4 + T cells, which paralleled their decreased gene expression ( Fig. 6d and Supplementary Fig. 4b ). Conversely, in group III genes, Tbx21, Gata3, Rorc, Smad3, Maf, and several chemokine receptors, both H3K27me3 and H3K4me3 levels were not dramatically changed (Fig. 6d and Supplementary Fig. 4c ). These histone methylation changes were further validated using ChIP-qPCR (Fig. 6e) . We found only a few genes that had histone methylation changes at distal regions ( Supplementary Fig. 5 ). These results suggest that Jmjd3 regulates target gene expression primarily through alterations in the histone methylation status of H3K27 and/or H3K4 in the promoter and gene body regions.
Jmjd3 interacts with transcription and epigenetic factors
We next determined whether Jmjd3 recruitment to specific gene promoters was mediated through interactions with transcription and epigenetic factors involved in T cell differentiation. Co-immunoprecipitation analyses revealed that Jmjd3 interacts with T-bet, but not Gata3, Foxp3, or RoRγt, in 293T cells ( Fig. 7a and Supplementary Fig. 3b ). Because H3K4 methylation levels were altered at many gene loci in Jmjd3-deficient T cells, we determined its interaction with key components of the H3K4 methyltransferase complex (Ash2L, RbBP5, and Wdr5). We found that Jmjd3 interacted with Ash2L, but not with RbBP5 or Wdr5, in 293T cells (Fig. 7b and Supplementary Fig. 3c ). Co-IP in 293T cells, cotransfected with T-bet and FLAG-tagged Ash2L, RbBP5 and Wdr5 plasmids, revealed that Tbet physically interacted with RbBP5 ( Fig. 7c and Supplementary Fig. 3d ). The endogenous interaction of Jmjd3 with Ash2L and T-bet was observed in WT but not in Jmjd3 cKO T cells ( Fig. 7d and Supplementary Fig. 3e ). Although T-bet interacts with Jmjd3 and RbBP5, a core protein of the H3K4 methyltransferase complex 39 , it is unclear whether Jmjd3 is required for T-bet-RbBP5 interaction. Immunoprecipitation and immunoblot analysis revealed that T-bet interacted with RbBP5 in the presence of Jmjd3, but failed to interact in Jmjd3-deficient T cells (Fig. 7e and Supplementary Fig. 3f ). To determine the functional relevance, we performed ChIP-quantitative PCR (qPCR) analysis of Cxcr3 and Ifng promoter regions in WT and Jmjd3 cKO Th1 cells and CD4 + SP thymocytes. Consistent with our previous observations, Jmjd3-deficient T cells disrupted the endogenous T-betRbBP5 interaction and markedly reduced T-bet binding to the promoter regions of Cxcr3, Ifng, and Cd44 genes ( Fig. 7f and Supplementary Fig. 6a ). These results suggest that Jmjd3 is required for T-bet and Ash2L to form a stable complex capable of binding to specific target gene promoters. Jmjd3 deficiency might destabilize this complex formation and reduce T-bet binding to Cxcr,Ifng, and Cd44 promoters, leading Cxcr3, Ifng, and Cd44 gene expression downregulation.
Smad3 has been reported to enhance Treg cell differentiation and inhibit Th17 cell differentiation 46 . Immunoprecipitation analysis revealed that Jmjd3 strongly and specifically interacts with Smad3, but not Smad1 or Smad2, in 293T cells (Fig. 7g and Supplementary  Fig. 3g ). This interaction was also observed in WT, but not in cKO CD4 + T cells derived from thymus ( Fig. 7h and Supplementary Fig. 3h,6b ). To identify a potential link between Jmjd3 deficiency and H3K4 methylation in the Foxp3 promoter region, we found specific interactions between Smad3 and Ash2L of the H3K4 methyltransferase complex (Fig. 7i and Supplementary Fig. 3i ), which was further confirmed in Treg cells (Supplementary Fig. 6c ). Immunoprecipitation analysis revealed that Smad3 interacted with Ash2L in the presence of Jmjd3, but failed to interact in Jmjd3-deficient Treg cells, suggesting that Jmjd3 is required for Smad3-Ash2L interaction ( Fig. 7j and Supplementary Fig. 3j ) (Fig. 7k) . Taken together, Jmjd3 regulates Foxp3 expression by stabilizing the Smad3-Ash2L-Jmjd3 complex.
To further validate the functional significance of the physical interactions between Jmjd3 and the transcription factors, we ectopically expressed Jmjd3 in CD4 + T cells under different cytokine conditions. Ectopic expression of Jmjd3 rescued transcription factor and target gene expression (Fig. 8a, Supplementary Fig. 7 ). ChIP-qPCR analysis revealed that Jmjd3 expression also rescued the binding of the T-bet to Cxcr3, Ifng, and Cd44 promoter regions, and restored the binding of Smad3 to the Foxp3 promoter (Fig. 8b,8c ). Taken together, our results indicate that Jmjd3 regulates T cell differentiation by interacting with specific transcription and epigenetic factors.
Discussion
CD4 + T cell subsets (Th1, Th2, Th17, and Treg cells) play an important role in cancer immunity and infectious and autoimmune diseases 2, 16 . Understanding the mechanisms that regulate and control T cell differentiation will lead to the development of innovative and effective strategies. It is known that the differentiation of naïve CD4 + T cells into the various T cell subsets is tightly regulated by various signaling molecules; however, the epigenetic regulation of T cell differentiation remains poorly understood.
Recent studies have suggested that epigenetic factors play an important role in CD4 + T cell differentiation [47] [48] [49] . Mixed-lineage leukemia-mediated H3K4 trimethylation has been implicated in the selective maintenance of memory Th2 cells to produce Th2 cytokines 49 , whereas the histone-lysine N-methyltransferase, Suv39h1, plays a critical role in maintaining the silencing of Th1 loci and modulating Th2 lineage stability and plasticity 47 . Our study provides evidence of the critical role of histone demethylase Jmjd3 in the epigenetic regulation of CD4 + T cell differentiation. T cell-specific Jmjd3 ablation inhibited Th1 and Treg cell differentiation and promoted Th2 and Th17 cell differentiation by regulating the expression of key T cell differentiation and transcription factors. In particular, the Th17 cell population is markedly increased in the small intestine and colon, but not in LN or spleen. We show that Jmjd3 regulates CD4 + T cell differentiation by controlling the methylation status of H3K27 and/or H3K4 in the promoter and body regions of target genes. Importantly, Jmjd3 is recruited to target gene loci through interactions with the transcription factors, T-bet and Smad3, and the epigenetic protein, Ash2L. However, it is not clear why Jmjd3 ablation has differential effects on different T cell subsets in different tissues. Thus, further investigation is required to address this issue.
Jmjd3 has been shown to regulate gene expression in a demethylase activityindependent 35, 40 and dependent manner 37, 38, 50 . To our knowledge, our study is the first to provide in vivo evidence of the essential role of Jmjd3 in Th1 and Treg cell differentiation through the demethylase-dependent regulation of Tbx21 (T-bet), Gata3, and Foxp3 expression. ChIP-Seq analysis showed a slight decrease in H3K4me3 in the promoter and gene body of Tbx21, Gata3, and Foxp3, whereas H3K4me3 and H3K27me3 levels in the promoter or gene body of Rorc were unchanged even though its expression was increased in Treg and Th17 cells. Tbx21 target gene expression decreased in Jmjd3-deficient T cells, whereas Jmjd3 and T-bet binding to the Tbx21 target gene promoter was abolished. Our findings indicate that Jmjd3 regulates Th1 differentiation through two mechanisms: 1) direct regulation of Tbx21 expression in a Jmjd3 demethylase activity-dependent manner; and 2) indirect regulation of Tbx21 expression through Jmjd3 and T-bet complex formation. Direct regulation of Tbx21 expression by Jmjd3 is consistent with a recent report showing that decreased Tbx21 methylation enhanced Th1 differentiation in Ezh2-deficient T cells 17 . Further investigation of the mechanistic details by which Jmjd3 binds to the Tbx21 gene promoter to regulate Tbx21 expression is needed. Our study shows that demethylation of H3K27me3 by Jmjd3 is required for optimal T cell differentiation. Other studies have shown that Jmjd3 functions as a demethylase to control mesodermal and cardiovascular differentiation of mouse embryonic stem cells 50 and M2 macrophage differentiation 37, 38 . Furthermore, TGF-β-activated Smad2/3 proteins activate target gene expression by recruiting Jmjd3 to counteract Polycomb-mediated repressive H3K27me3 marks 35 . Stat4 recruits Jmjd3 to Th1 genes and affects the production of IFN-γ 51 . In contrast, Jmjd3 regulated T-bet target genes, including Ifng and Cxcr3, by promoting general chromatin accessibility in a demethylase activity-independent manner 40 . Recently, Jmjd3 was reported to regulate the expression of target genes, including Cxcr3 and Cd44, through a combination of demethylase-dependent and independent mechanisms. Some genes, with less H3K27 methylation in the absence of Jmjd3, may have been modulated due to a functional change in UTX (Kdm6A gene) or Ezh2. Jmjd3 controlled the transcriptional activity of poised RNA polymerase II by demethylating H3K27me3 and interacting with the transcription elongation factors, STP6, IWS1, SETD2, and CHD7 52 . Our findings are in agreement with a previous study demonstrating the requirement for Jmjd3 in RNA polymerase II progression through H3K27me3-enriched gene bodies of TGF-β-responsive genes 53 .
Jmjd3 is a H3K27 demethylase without specific DNA binding properties, and the mechanisms by which it regulates specific gene expression remain unknown. We found that Jmjd3 selectively regulates target gene expression through interactions with transcription factors and epigenetic proteins. Our study provides compelling evidence that in T cells, Jmjd3 specifically interacts with the key transcription factor, T-bet, and Ash2L, a core protein of the H3K4 methyltransferase complex. Consistent with our findings, previous studies have shown that Jmjd3 interacts with T-bet and another key component of the H3K4 methyltransferase complex, RbBP5, to regulate the expression of T-bet-dependent target genes, including Ifng and Cxcr3 39, 40 . Although we found that Jmjd3 does not directly interact with RbBP5, it may be required for the T-bet-RbBP5 interaction, because Jmjd3 deficiency disrupted the endogenous T-bet-RbBP5 interaction in T cells and diminished the ability of T-bet to bind to the promoter and gene body regions of Ifng and Cxcr3. Therefore, our results suggest that Jmjd3 binds to T-bet/RbBP5 and Ash2L to form a stable complex capable of binding to specific gene promoters. Consistent with these findings, Jmjd3 deficiency resulted in a downregulation of CXCR3 expression in T cells. In addition to T-bet and Ash2L, Jmjd3 may interact with other factors, ensuring target gene specificity. Optimal T-bet-dependent gene expression required the Jmjd3-mediated interaction between T-bet and the chromatin remodeling factor, Brg1 40 . Further studies are needed to identify other key transcription factors that interact and act in concert with Jmjd3 to regulate target gene expression.
This study is the first, to the best of our knowledge, to provide genetic evidence that Jmjd3 is required for CD4 + T cell differentiation in vitro and in vivo. These effects of Jmjd3 are mediated through the epigenetic regulation of T cell-related differentiation and transcription factors. Thus, our findings provide new insights into the role and molecular mechanism of action of Jmjd3 in CD4 + T cell differentiation. Based on our data, we propose a working model by which Jmjd3 regulates CD4 + T cell differentiation (Fig. 8d) . In this model, transcription factors, via Ash2L, recruit Jmjd3 interacting with a H3K4 methyltransferase complex, and then the transcription factor physically interacts with a protein within the H3K4 methyltransferase complex, such as RbBP5 or Ash2L. This forms a stable complex capable of binding to target gene promoters, allowing Jmjd3 to alter H3K27 methylation level and RbBP5 and Ash2L to alter H3K4 methylation level to control target gene expression. Jmjd3 upregulates Th1 and Treg cell differentiation factor expression, including Foxp3, Ifng, Cd44, and Cxcr3, and downregulates the expression of Th2 and Th17 differentiation factors, including Gata3 and Rorc. These Jmjd3-mediated gene expression changes lead to the promotion of Th1 and Treg cell differentiation and the inhibition of Th2 and Th17 cell differentiation.
Methods
Mice
Jmjd3 flox/flox (Jmjd3 f/f ) mice were generated by targeting exons 15-21 (encoding the JmjCcatalytic domain) using a Cre-LoxP system. Eight-week-old Jmjd3 f/f male mice were crossed with eight-week-old CD4-Cre female mice (Taconic) to generate Jmjd3 cKO mice. C57BL/6 and 2D2 mice were obtained from the Jackson Laboratory. Rag2 −/− γc −/− mice were purchased from Taconic. Foxp3-GFP reporter mice were kindly provided by Dr. Alexander Rudensky (Memorial Sloan-Kettering Cancer Center, NY). All mice were rederived by standard embryo transfer and maintained in pathogen-free animal facilities at Baylor College of Medicine and the Houston Methodist Research Institute. This study was reviewed and approved by Institutional Animal Care and Use Committee at Baylor College of Medicine and the Houston Methodist Research Institute.
Splenocyte purification and CD4 + T cell differentiation
Mouse splenocytes were isolated using a negative selection kit (StemCell) and stained for CD4 (anti-CD4-PE, GK1.5, Biolegend. 1:100 dilution), CD25 (anti-CD25-eFluo450, eBioscience 48-0251-82, 1:100 dilution), CD44 (anti-CD44-APC-eFluo780, clone IM7, eBioscience, 1:100 dilution), and CD62L (anti-CD62LFITC, eBioscience 11-0621-85, 1:100 dilution). Naïve CD4 + (CD4 + CD25 − CD44 low CD62L + ) cells were sorted by BD FACSAria II to > 95% purity. For in vitro activation, CD4 + T cells were stimulated with 0.5 μg/mL soluble anti-CD3 and 1 μg/mL anti-CD28 in the presence of 3000 rads-irradiated T celldepleted splenocytes as antigen-presenting cells. RPMI medium was supplemented with 10% fetal calf serum, L-glutamine (2 mM), 2-mercaptoethanol (55 μM), penicillin (50 U/ mL), streptomycin (50 mg/mL), sodium pyruvate (1 mM), and HEPES (25 mM). Conditions for CD4 + T cell differentiation were as follows: Th1 cells, IL-12 (10 ng/mL) + IL-2 (60 IU/ mL); Th2 cells, IL-4 (10 ng/mL) + IL-2 (60 IU/mL); Th17 cells, recombinant human (rh)TGFβ1 (5 ng/mL) + IL-6 (20 ng/mL); and Treg cells, rhTGFβ1 (5 ng/mL) + IL-2 (60 IU/ mL).
Isolation of intestinal lymphocytes
Mice were sacrificed and intestines were removed and placed in ice-cold phosphate-buffered saline (PBS). After removal of residual mesenteric fat tissue, Peyer's patches were carefully excised, and the intestine was opened longitudinally. The intestine was thoroughly washed in ice-cold PBS and cut into 0.3-0.5 cm pieces. The pieces were incubated in 20 mL of 2 mM EDTA in 10% fetal bovine serum (FBS)/PBS for 20 min at 37°C with slow rotation. After incubation, the epithelial cell layer was removed by intensive vortexing and was passed through a 70-μm cell strainer. The pieces were washed once with PBS, and placed in 20 mL of digestion solution containing 10% FBS and 0.5 mg/mL of Collagenase IV (Sigma). Digestion was performed by incubating the pieces at 37°C for 60 min with slow rotation. After the initial 60 min, the solution was vigorously vortexed and passed through a 40-μm cell strainer. The pieces were collected and placed into fresh digestion solution, and the procedure was repeated a total of two times. Supernatants from both digestions were combined, centrifuged, and washed once in PBS. The cells were resuspended in 44% (vol/ vol) Percoll (GE Healthcare Bio-Sciences, Piscataway, NJ), overlaid on 5 mL of 67% Percoll in a 15-mL Falcon tube, and centrifuged for 20 min at 625 × g at room temperature. Lamina propria lymphocytes were collected at the interphase of the Percoll gradient, washed twice, and used immediately for experiments 54 .
Flow cytometry and enzyme-linked immunoabsorbent assay
For detection of surface molecules, T cells were first incubated with an anti-Fc receptor Ab (24G2) to reduce the nonspecific binding of the monoclonal antibodies (mAbs), and then labeled with the appropriate fluorescent mAbs. For the analysis of intracellular cytokine production, T cells were stimulated with phorbol 12-myristate 13-acetate (PMA; 50 ng/mL) and ionomycin (1 μg/mL) for 4 h in the presence of Golgi Stop solution (BD Biosciences). Cells were harvested, washed, fixed, permeabilized (FIX AND PERM, Invitrogen), and stained with fluorescein-labeled cytokine-specific mAbs according to the manufacturer's instructions. Appropriate fluorescein-conjugated, isotype-matched mAbs were used as negative controls. Cells were analyzed using the BD FACS Aria II. IFN-γ and IL-4 production were determined using ELISA kits (R&D Systems) according to the manufacturer's protocols.
In vivo differentiation of naïve CD4 + T cells
For long-term T cell differentiation, a CD4 + T cell-dependent colitis model was used. Naïve CD4 + T cells (CD4 + CD25 − CD62L + CD44 low ) and Treg cells (CD4 + CD25 + ) from eightweek-old WT and Jmjd3 cKO female mice were purified by FACS, resuspended by gently mixing, and i.p. injected into sublethally irradiated eight-week-old Rag2 −/− γc −/− female mice (1 × 10 6 T cells, or 1 × 10 6 T cells + 0.2 × 10 6 Treg cells per mouse). Two weeks later, treated mice were monitored daily for disease progression based on body weight loss, and T cell subsets in spleen and intestines were determined at day 29 and day 40 after T cell transfer. The intestinal inflammation was scored based on: the affected tissue area; the epithelial hyperplasia and goblet cell deficiency; leukocyte infiltration in the lamina propria; and the appearance of inflammation markers, including submucosal inflammation and crypt abscesses. For short-term in vivo differentiation, naïve CD4 + T cells (CD4 + CD25-CD62L + CD44 low ) from eight-week-old WT and Jmjd3 cKO female mice were intravenously injected into sublethally irradiated eight-week-old Rag2 −/− γc −/− female mice (250 rads). On day 10 after adoptive transfer of naïve CD4 + T cells, spleens were removed and splenocytes were prepared for determination of various CD4 + T cell subsets by FACS analysis.
RNA preparation, RT-PCR, and qPCR
Total RNAs were isolated from T cells with Trizol reagent (Invitrogen). A total of 0.5 μg of RNA was converted to cDNA using SuperScript III Reverse Transcriptase (Qiagen) with random hexamer primers. qPCR was performed using the ABI Prism 7000 Analyzer (Applied Biosystems) with SYBR Green mix (Applied Biosystems). All primers are listed in Supplementary Table 2 .
Immunoblotting analysis
Cells were harvested and lysed in RIPA buffer with protease inhibitors and 2 μM PMSF. Protein extracts were boiled in SDS sample buffer for 5 min, loaded directly onto a 4-12% SDS gel, transferred onto nitrocellulose membranes (Bio-Rad), blocked with 5% milk, and incubated with corresponding primary and secondary antibodies using standard protocols. The following antibodies were used: anti-H3K4me1 (Cat # 07-436, 1:2000 dilution), antiH3K4me2 (Cat # 07-030, 1:4000 dilution), anti-H3K4me3 (Cat # 07-473, 1:4000 dilution), anti-H3K9me1 (Cat # 07-450, 1:2000 dilution), anti-H3K9me2 (Cat # 07-441, 1:3000 dilution), anti-H3K9me3 (Cat # 07-442, 1:3000 dilution), anti-H3K27me1 (Cat # 07-448, 1:2000 dilution), anti-H3K27me2 (Cat # 07-452, 1:4000 dilution), and anti-H3K27me3 (Cat # 07-449, 1:4000 dilution) from Millipore; rabbit anti-Jmjd3 (Cat # ab1022a, 1:500 dilution) from Abgent; and mouse anti-FLAG (1:5000 dilution), anti-HRP-FLAG (1:5000 dilution), and anti-β-actin (1:5000 dilution) from Sigma; anti-Smad1 (Cat # 6944, 1:500 dilution), anti-Smad2 (Cat # 5339, 1:500 dilution) and anti-Smad3 (Cat # 9523, 1:500 dilution) from Cell Signaling; and anti-Ash2L (Cat # ab50699, 1:500 dilution) from Abcam.
ChIP-Seq and ChIP-PCR analyses
A total of 200 ng of DNA from WT and Jmjd3 cKO CD4 + T cells was used for the ChIPSeq library construction. Illumina sequencing was performed according to previously described protocols 44, 55, 56 . Sequencing reads from H3K4me3 and H3K27me3 ChIP-Seq libraries were aligned to the mouse mm8 genome using ELAND software. To reduce PCR amplification bias, only one uniquely mapped read per genomic position was retained. The histone modification changes upon Jmjd3 knockout were assessed as follows. The H3K27me3 sequencing reads in WT and cKO samples were counted in 4 Kb windows centered at TSS or p300 ChIP-Seq peaks. The resulting read counts were used as input to the DEGseq algorithm 56 to identify differentially methylated genes and enhancers. The DEGseq q-value cutoff of 0.05 and the fold-change cutoff of 2 were used to identify statistically significant methylation changes. The GEO accession number for the raw and analyzed ChIP-seq data is GSE58775. ChIP-PCR experiments were performed using the Imprint Chromatin Immunoprecipitation Kit (Sigma) according to the manufacturer's instructions. All primers are listed in Supplementary Table 2 .
Statistical analysis
Data are reported as the mean ± standard deviation (SD) where indicated. Differences between groups were analyzed using the Student's t-test with GraphPad Prism 4.0 software. A p value < 0.05 was considered statistically significant.
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